TipRanks

Notifications

Mainz Biomed B.V. (MYNZ) Q1 Earnings Cheat Sheet

Mainz Biomed B.V. (MYNZ) is scheduled to report 1st quarter earnings on 05/16/2023.

Regarding Q1 estimates, Wall Street analysts expect Mainz Biomed B.V. to post earnings of -$0.49 per share. Revenue expectations are pegged at $267 thousand. Last quarter, Mainz Biomed B.V. beat earnings estimates, reporting EPS of -$0.46 on estimates of -$0.46. The stock fell by -0.57% the day after the last earnings release.

Year-to-date, MYNZ stock has fallen by -21.36%.

Is Mainz Biomed B.V. Stock a Buy?

Wall Street’s consensus rating for MYNZ stock is a Moderate Buy, with an average analyst price target of $10.50, implying upside potential of 102.31% from current levels.

MYNZ shares have lost about -33.97% in the past six months.

About Mainz Biomed B.V.

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It’s main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.

Tags: ,